ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 192

Comparison of Bone Scan with Xiralite (FOI) in Patients with Rheumatoid Arthritis and Psoriatic Arthritis

Joerg Polter, Susanne Drynda and Jörn Kekow, Clinic for Rheumatology, Vogelsang-Gommern, Germany

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: imaging techniques, psoriatic arthritis and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 8, 2015

Title: Imaging of Rheumatic Diseases Poster I: Ultrasound, Optical Imaging and Capillaroscopy

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose:

In recent years Xiralite, an ICG-enhanced fluorescence optical imaging (FOI) technology, has gained growing importance as a non-radioactive imaging technique for the detection of inflammatory processes in joints [1]. It was the objective of our study to compare this new technique with conventional bone scans and with clinical findings in rheumatoid arthritis (RA) and psoriatic arthritis (PsA) patients.

Methods:

420 joints of 14 RA patients and 350 joints of 11 PsA patients were analysed by Xiralite, bone scan, and clinical evaluation. Due to the Xiralite system, both hands were the ROI in the study.

 Results:

In the RA cohort, 94 out of 420 joints (22%) were identified as inflamed using the bone scan. By means of Xiralite, 97 (23%) inflamed joints were detected. In the clinical examination, 82 joints (19.5%) were found to be swollen.

In PsA patients 48 (14.5%) and 63 (19%) joints were found inflamed using the bone scan and Xiralite, respectively, and 42 out of 330 joints (13%) were swollen.

In 11 out of 14 RA patients (78.5%) and 8 out of 11 PsA patients (75%) the Xiralite and the bone scan produced consistent results in at least 50% of the number of inflamed joints. In 9 RA patients and 4 PsA patients the consistency of both methods was even 75% and higher.

 Conclusion:

Our data show comparable numbers of inflamed joints identified by Xiralite and the traditional bone scan with a high degree of consistency. Both techniques have been found equivalent for the identification of affected joints and superior to clinical evaluation. In PsA Xiralite identifies even more inflamed joints than to a bone scan.

 References

[1] Werner, SG, Langer HE, Ohrndorf S et al. Inflammation assessment in patients with arthritis using a novel in vivo fluorescence optical imaging technology. Ann Rheum Dis 2011; 71:504-510


Disclosure: J. Polter, None; S. Drynda, None; J. Kekow, None.

To cite this abstract in AMA style:

Polter J, Drynda S, Kekow J. Comparison of Bone Scan with Xiralite (FOI) in Patients with Rheumatoid Arthritis and Psoriatic Arthritis [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/comparison-of-bone-scan-with-xiralite-foi-in-patients-with-rheumatoid-arthritis-and-psoriatic-arthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/comparison-of-bone-scan-with-xiralite-foi-in-patients-with-rheumatoid-arthritis-and-psoriatic-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology